IGF-1 DES (Des(1-3) IGF-1)

Truncated IGF-1 Analog | Localized Muscle Growth

Weight: ~7,000 Da
Half-life: 20-30 minutes
Chain: 67 amino acids
4 studies
2020 latest
Limited Research
Dose 20-50mcg post-workout (site-specific IM injection)
Frequency Post-workout only, injected into trained muscle
Cycle 4-6 weeks maximum
Storage Lyophilized: -20C. Reconstituted: 2-8C, use within 7 days (BAC water)
Accumulation Plotter

Community Research

Join others researching IGF-1 DES — share findings, ask questions, and learn from real experiences

View Results Aggregated community findings
Discussion Questions & experiences
Submit Your Findings Contribute your research data

IGF-1 DES (Des(1-3) IGF-1) is a truncated analog of insulin-like growth factor-1, missing the first three N-terminal amino acids. This structural modification eliminates binding to IGF binding proteins (IGFBPs), meaning 100% of the peptide is bioactive rather than being sequestered in circulation. The result is approximately 10x greater potency than native IGF-1, but with an extremely short half-life of 20-30 minutes. This short duration of action is considered a feature rather than a limitation -- it allows for site-specific injection into target muscles immediately post-workout, promoting localized growth with reduced systemic exposure.

Mechanism of Action

IGF-1 DES activates the IGF-1 receptor (IGF-1R) and downstream PI3K/Akt/mTOR and MAPK/ERK signaling pathways, driving both muscle hypertrophy and hyperplasia. Because it lacks the tripeptide Gly-Pro-Glu at the N-terminus, it cannot bind to IGFBPs that normally sequester ~98% of circulating IGF-1. This means the entire administered dose remains bioavailable. The very short half-life confines its activity to the local injection site, where it stimulates satellite cell proliferation and differentiation, protein synthesis, and nutrient uptake in the targeted muscle tissue.

01 Approximately 10x more potent than native IGF-1
02 100% bioactive -- does not bind to IGF binding proteins
03 Extremely short half-life enables localized, site-specific action
04 Promotes satellite cell activation for muscle hyperplasia
05 Minimal systemic exposure compared to IGF-1 LR3

Molecular Data

Molecular Weight
~7,000 Da
Chain Length
67 amino acids
Type
Truncated IGF-1 analog
Peak 0.0 mcg
Trough 0.0 mcg
SS Peak 0.0 mcg
SS Trough 0.0 mcg

Research Indications

Muscle Growth
Localized Hypertrophy most effective

Site-specific muscle growth via direct intramuscular injection into target muscle post-workout.

Hyperplasia effective

Stimulates satellite cell proliferation and differentiation, potentially creating new muscle fibers.

Recovery effective

Accelerates local tissue recovery in the injected muscle group after training.

Tissue Repair
Local Tissue Repair moderate

Promotes repair and regeneration at the injection site through IGF-1R activation.

Dosing Protocols

Intramuscular injection directly into the target muscle immediately post-workout. The extremely short half-life means timing and site selection are critical. Consume fast carbohydrates after injection to mitigate hypoglycemia risk.

GoalDoseFrequencyRoute
Beginner Protocol20-30mcgPost-workout, injected into trained muscleIM (site-specific)
Intermediate30-50mcgPost-workout, injected into trained muscleIM (site-specific)
Advanced50mcgPost-workout, split across multiple trained musclesIM (site-specific)

Reconstitution Instructions

Materials Needed:
  • IGF-1 DES lyophilized powder
  • Bacteriostatic water or 0.6% acetic acid
  • Insulin syringes (29-31 gauge)
  • Alcohol swabs
  1. 1 Allow vial to reach room temperature (15-30 min)
  2. 2 Sanitize rubber stopper with alcohol swab
  3. 3 Calculate desired concentration (e.g., 1mg in 1mL = 1000mcg/mL)
  4. 4 Inject diluent slowly along the vial wall
  5. 5 Gently swirl -- do not shake
  6. 6 Allow 2-5 minutes for complete dissolution
  7. 7 Store reconstituted solution at 2-8C
  8. 8 Use within 7 days when reconstituted with BAC water
  9. 9 Acetic acid reconstitution extends stability

Interactions

++
Human Growth Hormone
HGH raises baseline IGF-1 levels; adding IGF-1 DES post-workout provides a localized anabolic spike on top of elevated systemic IGF-1. Use with caution and monitor blood glucose.
synergistic
~
IGF-1 LR3
Do not stack with IGF-1 DES. Both are IGF-1 analogs acting on the same receptor. Choose one or the other based on whether you want systemic (LR3) or localized (DES) effects.
monitor
++
Testosterone
Testosterone increases IGF-1 receptor density and satellite cell number, amplifying the local effects of IGF-1 DES at the injection site.
synergistic
!
Insulin
Both lower blood glucose. Combining IGF-1 DES with exogenous insulin significantly increases hypoglycemia risk.
avoid

What to Expect

Immediately post-injection
Localized muscle pump and fullness in the injected muscle within minutes; possible mild hypoglycemia
Week 1-2
Noticeable pump and fullness in targeted muscles on training days; localized soreness at injection site
Week 3-4
Visible improvements in targeted muscle size and shape; enhanced recovery between sessions
Post-cycle
Effects diminish rapidly due to the short-acting nature; structural gains from hyperplasia may persist

Side Effects & Safety

Common Side Effects

  • Hypoglycemia -- consume carbohydrates after injection
  • Localized swelling and soreness at injection site
  • Increased pump in targeted muscles
  • Mild lightheadedness shortly after injection

Stop Signs - Discontinue if:

  • Severe or recurring hypoglycemia despite carbohydrate intake
  • Disproportionate or asymmetric muscle growth
  • Unusual growths, lumps, or rapid mole changes
  • Persistent pain, redness, or infection at injection site
  • Signs of systemic IGF-1 excess (jaw growth, organ enlargement)

Contraindications

  • Not approved for human use -- research chemical only
  • Cancer history or active malignancy (IGF-1 promotes cell proliferation)
  • Diabetes or impaired glucose regulation
  • WADA prohibited substance -- causes failed drug tests

Quality Checklist

Good Signs

  • HPLC purity >95%
  • Mass spectrometry confirmation of truncated sequence
  • Cold storage maintained (-20C lyophilized)
  • Certificate of analysis from reputable source

Warning Signs

  • Research chemical only -- never approved for human use
  • No human clinical trials exist
  • Extremely short half-life requires precise timing

Bad Signs

  • Hypoglycemia risk -- blood sugar can drop rapidly after injection
  • Potential for disproportionate muscle growth with repeated site-specific use
  • Black market quality varies -- degraded product is common
  • Cancer proliferation concern -- elevated IGF-1 activity promotes cell growth

References

  • The isolation and characterization of a naturally occurring truncated form of IGF-I in human brain
    Sara VR, Carlsson-Skwirut C, Andersson C, Hall E, Sjogren B, Holmgren A, Jornvall H
    Biochemical and Biophysical Research Communications (1986)

    First identification and characterization of Des(1-3) IGF-1 as a naturally occurring truncated form of IGF-1 in human brain tissue, establishing that the N-terminal tripeptide deletion occurs endogenously.

  • Des(1-3)IGF-I: A truncated form of insulin-like growth factor-I that has greatly enhanced activity in promoting growth
    Francis GL, Ross M, Ballard FJ, Milner SJ, Senn C, McNeil KA, Wallace JC, King R, Wells JR
    Journal of Molecular Endocrinology (1992)

    Des(1-3) IGF-1 demonstrated approximately 10-fold greater potency than intact IGF-1 in stimulating protein synthesis and cell proliferation, directly attributable to its inability to bind IGF binding proteins.

  • Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats
    Tomas FM, Knowles SE, Owens PC, Chandler CS, Francis GL, Read LC, Ballard FJ
    Biochemical Journal (1992)

    Des(1-3) IGF-1 and LR3-IGF-1 were significantly more potent than native IGF-1 in reversing dexamethasone-induced muscle wasting in rats, with truncated and modified variants showing superior anabolic activity.

  • Circulating Insulin-like Growth Factor-I Concentrations and Risk of 30 Cancers: Prospective Analyses in UK Biobank
    Murphy N, Knuppel A, Papadimitriou N, Martin RM, Tsilidis KK, Brennan P et al.
    Cancer Research (2020)

    Higher circulating IGF-1 associated with increased risks of colorectal, breast, prostate, and thyroid cancers in >395,000 UK Biobank participants, underscoring the cancer risk of sustained IGF-1 pathway activation.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.